The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal c (Q35569473)
Jump to navigation
Jump to search
scientific article published on 16 October 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal c |
scientific article published on 16 October 2011 |
Statements
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design (English)
Andrew J Stewart Coats
Venkatesan Srinivasan
Jayaraman Surendran
Haritha Chiramana
Shankar R K G Vangipuram
Nirajkumar N Bhatt
Minish Jain
Sandip Shah
Ho G Fuang
Mohammed Z M Hassan
John Beadle
Julia Tilson
on behalf of the ACT-ONE Trial Investigators
Stefan D Anker
16 October 2011
1 reference
1 reference